Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

about

Epigenetics and trained immunity.

P2860

Q41991194-694282EB-6F7B-4007-8EAC-72413AF55CE3

P2860

Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

Item

http://www.wikidata.org/entity/Q51023485

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Histone Deacetylase Inhibitor ...... nd Inflammatory Breast Cancer.

@en

Histone Deacetylase Inhibitor ...... nd Inflammatory Breast Cancer.

@nl

type

Item

label

Histone Deacetylase Inhibitor ...... nd Inflammatory Breast Cancer.

@en

Histone Deacetylase Inhibitor ...... nd Inflammatory Breast Cancer.

@nl

prefLabel

Histone Deacetylase Inhibitor ...... nd Inflammatory Breast Cancer.

@en

Histone Deacetylase Inhibitor ...... nd Inflammatory Breast Cancer.

@nl

P1476

Histone Deacetylase Inhibitor ...... and Inflammatory Breast Cancer

@en

P2093

Debu Tripathy

http://www.w3.org/2001/XMLSchema#string

Jangsoon Lee

http://www.w3.org/2001/XMLSchema#string

Naoto T Ueno

http://www.w3.org/2001/XMLSchema#string

Peter Ordentlich

http://www.w3.org/2001/XMLSchema#string

Takahiro Kogawa

http://www.w3.org/2001/XMLSchema#string

P2860

Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency

Structural insights into the degradation of Mcl-1 induced by BH3 domains

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression

Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells

MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells

Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers.

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

P304

4780-4792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-16-2622

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bora Lim

Angie M Torres-Adorno

P577

2017-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28465444

http://www.w3.org/2001/XMLSchema#string

P932

5559319

http://www.w3.org/2001/XMLSchema#string

Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

about

P2860

P2860

Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932